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Abstract 
 
Background 
Anticoagulation with warfarin is an important therapy for preventing strokes in pa-
tients with atrial fibrillation (AF). Physicians often combine warfarin with aspirin 
despite evidence for increased bleeding. We investigated the hemorrhagic out-
comes related to the differential management of AF with warfarin alone versus 
combination therapy. 
 
Methods and Results 
This retrospective cohort study of 695 patients enrolled at a university hospital-
based anticoagulation clinic includes patients who received anticoagulation with 
warfarin or warfarin and aspirin between June 1, 2007 and September 30, 2008. 
All patients were ≥45 years old, had AF as the indication for anticoagulation, and 
did not have mechanical heart valves. Hemorrhages were classified as major if 
they caused death, involved critical sites, or required hospitalization with transfu-
sion of ≥2 units of blood. All other bleeds were classified as minor. Of the 695 
patients 307(44.2%) received combination therapy. Hemorrhage rates in the war-
farin and the combination cohorts were 5.2% and 7.0% per 100-people years 
(p=0.29), respectively. There were 17 (3.4%) patients with major hemorrhages in 
the warfarin only group and 9 (2.8%) in the combination group (p=0.62). On aver-
age, patients on combination therapy had lower international normalized ratio 
(INR) values circa presentation (4.27 vs 3.13 p=0.049). In either group, any histo-
ry of hemorrhage was associated with a 3.8 (95% CI, 1.79-8.13) times higher risk 
of hemorrhaging compared to patients without such a history. 
 
Conclusions 
This study highlights the high incidence of combination therapy and suggests that 
patients on combination therapy may bleed at lower INR levels. However, hemor-
rhagic outcomes did not differ significantly. 
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Introduction 
 
Oral anticoagulation with vitamin K antago-
nists, such as warfarin, reduces the risk of 
stroke in patients with atrial fibrillation by up 
to 60% thereby preventing serious morbidity 
and mortality.1-3  Warfarin is also effective in 
preventing coronary artery thrombosis, 
though it is not often used for this indica-
tion.4-6  The significant bleeding risks associ-
ated with warfarin mandate close monitoring 
and have limited its broader application.7-9 
Antiplatelet agents, specifically aspirin, tend 
to reduce the risk of stroke in patients with 
atrial fibrillation, although less effectively 
than warfarin does.10  Aspirin and 
clopidogrel, often in combination, are used to 
prevent coronary artery thrombosis in pa-
tients with coronary artery disease, especially 
following coronary artery stent deploy-
ment.11  In patients with coronary artery dis-
ease and atrial fibrillation, previous studies 
have reported a high incidence of combina-
tion warfarin and aspirin therapy.12  Combi-
nation therapy has been associated with an 
increased risk of hemorrhage, but has ill-
defined antithrombotic benefit over warfarin 
alone.13,14  
 
The primary goal of this study was to better 
characterize the demographics of patients 
who are placed on combination therapy and 
how the different treatment regimens affect 
hemorrhagic risk.  Furthermore, we aimed to 
identify independent risk factors predictive 
of hemorrhagic events.  We hypothesized 
that atrial fibrillation patients would be more 
likely to be on combination therapy if they 
have coronary artery disease risk factors.  We 
also predicted that receiving combination 
therapy would increase the risk of clinically 
significant bleeding, especially major bleed-
ing events. 
 
 
 
Methods 
 
We performed a retrospective cohort study of 
patients with atrial fibrillation who were 
treated with warfarin alone or combination 
warfarin and aspirin at a university-based 
anticoagulation clinic.  This study was ap-
proved by the institutional review board of 
the University of Massachusetts Medical 
School, Worcester, MA.  The inclusion crite-
ria included 1) receiving oral anticoagulation 
with warfarin or warfarin and aspirin be-
tween June 1, 2007 and September 30, 2008 
under the direction of the anticoagulation 
clinic, 2) atrial fibrillation as the indication 
for anticoagulation, 3) hospital and anticoag-
ulation clinic electronic medical records up-
dated during the study period, and 4) age ≥45 
years on June 1, 2007.  Patients with me-
chanical heart valves and those taking 
clopidogrel were excluded.  Patients with 
non-mechanical bio-prosthetic valves were 
not excluded. 
 
By searching the anticoagulation clinic medi-
cal records for patients with atrial fibrillation, 
832 patients were identified and screened for 
eligibility.  Of these patients 137 were ex-
cluded. Reasons for exclusion included in-
complete medical records (66), clopidogrel 
use (38), mechanical heart valve (30), and 
age less than forty-five (3).  We identified 
695 (83.5%) patients with atrial fibrillation 
who were 45 years or older, did not have a 
mechanical heart valve, and had electronic 
hospital and anticoagulation clinic records 
updated during the study period.  We collect-
ed demographic, comorbidity, medication, 
laboratory, and hemorrhagic outcome data 
over the period of 16 months by searching 
and reviewing the anticoagulation clinic and 
affiliated hospital electronic records.  A 
small cohort of an additional 36 patients on 
warfarin, aspirin, and clopidogrel was also 
identified.  This subgroup will be referred to 
as the triple therapy group.  The triple thera-
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py group was considered separately from the 
main study group.  Two patients were on 
warfarin and clopidogrel without aspirin. 
These two patients were excluded from the 
subgroup analysis due to the small cohort 
size. 
 
Exposure time to warfarin and aspirin thera-
py was calculated as follows.  We counted 
June 1, 2007 as the start date for patients en-
tering the study already on warfarin alone or 
combination.  For those who initiated warfa-
rin therapy during the study time, exposure 
length was calculated, and averaged into the 
final data proportionally.  Warfarin therapy 
start and stop dates were derived from the 
anticoagulation clinic records.  Exposure 
time ceased on September 30, 2008 or earlier 
if warfarin was permanently discontinued or 
death occurred.  If warfarin was discontinued 
or if death occurred, then calculation of ex-
posure to other medications and the follow-
ing of outcomes stopped.  If patients on com-
bination therapy stopped taking aspirin dur-
ing the study, then the time off aspirin ac-
crued towards the warfarin alone group. 
Likewise, if patients on warfarin only thera-
py started aspirin during the study, then that 
time accrued towards the combination group. 
Refer to Table 1 for warfarin exposure dura-
tions.  Exposure to warfarin before June 1, 
2008 was indexed as “None”, <90 days, 90 
days to 1 year, and ≥ 1 year.   
 
CHADS2 scores were calculated for all pa-
tients.  Patients received a score of 0 to 6 de-
pending upon their risk factors which were 
identified by reviewing the anticoagulation 
clinic and hospital electronic records.  Pa-
tients were given one point for each of the 
following risk factors: congestive heart fail-
ure, hypertension, age >75 years on June 1, 
2007, and diabetes mellitus.  Patients re-
ceived two points for a history of stroke or 
transient ischemic attack.15 
 
The primary outcome was any clinically sig-
nificant hemorrhagic events which were clas-
sified as major or minor.  Major hemorrhag-
es, as previously defined by Hylek et al 
2007,9 included any which were fatal, re-
quired hospitalization and transfusion of ≥2 
units of packed red blood cells, or involved a 
critical site (i.e. retroperitoneal, intraocular, 
intracranial, etc).  All hemorrhages not meet-
ing these criteria were classified as minor.  In 
most cases, INR values were measured upon 
presentation for hemorrhage.  In four cases, 
INR values were not available upon admis-
sion.  Two of the four patients had INR 
measured within one day of evaluation for 
hemorrhage, one within three days, and one 
within five days.  Not all patients were ad-
mitted when they presented with hemorrhag-
es and some were admitted to outside facili-
ties from which we could not obtain admis-
sion INR values. 
 
Statistical Analysis 
 
Data were analyzed using SAS software re-
lease 9.1.3 (SAS Institute, Cary, NC).  Con-
tinuous variables were tested for statistical 
significance using the t-test.  Categorical var-
iables were tested with chi-square analysis. 
Statistical significance was defined by p < 
0.05 for all tests. 
 
Multivariate analysis using logistic regres-
sion was performed in order to examine like-
lihood of bleeding while adjusting for varia-
bles of interest.  These variables included 
patient demographics, coronary artery dis-
ease, CHADS2 score, history of warfarin ex-
posure, prior bleeding history and dual thera-
py.  All variables that were significant at the 
level of p < 0.25 at the univariate level were 
also included in the logistic regression.  A 
Hosmer-Lemeshow goodness-of-fit test was 
performed to confirm the final model.  All 
results in the regression model were repre-
sented by an odds ratio and 95% confidence  
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Table 1: Patient characteristics* 
Characteristic Overall 
n=695 (100%) 
Warfarin 
n=388 (55.8%) 
Combination 
n=307 (44.2%) 
p Value 
Age         
     Mean (±Std Dev) 72.9 (±10.3) 73.5 (±10.7) 72.0 (±9.7) 0.06 
     Median 74 75 73   
Female 286 (41.2) 193 (49.7) 93 (30.3) <0.001 
Paroxysmal 149 (21.4) 76 (19.6) 73 (23.8) 0.18 
Warfarin Exposure Timea       0.36 
    None 197 (28.4) 102 (26.3) 96 (30.9)   
    <90 days 36 (5.2) 20 (5.2) 16 (5.2)   
    ≥90 days but <1 year 92 (13.2) 48 (12.4) 44 (14.3)   
    ≥1 year 370 (53.2) 218 (56.2) 152 (49.5)   
CHADS2 Score       0.49 
     0 38 (5.5) 25 (6.4) 13 (4.2)   
     1 162 (23.3) 92 (23.7) 70 (22.8)   
     2 244 (35.1) 127 (32.7) 117 (38.1)   
     3 133 (19.1) 78 (20.1) 55 (17.9)   
    ≥4 118 (17.0) 66 (17.0) 52 (16.9)   
Cardiovascular History         
    Hypertension 594 (85.5) 327 (84.3) 267 (87.0) 0.32 
    Dyslipidemia 475 (68.4) 237 (61.1) 238 (77.5) <0.001 
    Myocardial infarction 132 (19.0) 34 (8.8) 98 (31.9) <0.001 
    Coronary artery disease 290 (41.7) 105 (27.1) 185 (60.3) <0.001 
    Coronary artery stent 76 (10.9) 20 (5.2) 56 (18.2) <0.001 
    CABGb 106 (15.3) 33 (8.5) 73 (23.8) <0.001 
    Heart Failure 199 (28.6) 108 (27.8) 91 (29.6) 0.60 
    Stroke or TIAc 137 (19.7) 76 (19.6) 61 (19.9) 0.93 
    Pacemaker/Defibrillator 157 (22.6) 76 (19.6) 81 (26.4) 0.03 
Other Characteristics         
    Diabetes Mellitus 184 (26.5) 87 (22.4) 97 (31.6) 0.007 
    Renal Failured 95 (13.7) 53 (13.7) 42 (13.68) 0.99 
    Liver Diseasee 20 (2.9) 12 (3.1) 8 (2.6) 0.70 
    Hypothyroidism 113 (16.3) 65 (16.8) 48 (15.6) 0.92 
    Malignancyf 98 (14.1) 59 (15.2) 39 (12.7) 0.35 
    Obstructive Sleep Apnea 89 (12.8) 42 (10.8) 47 (15.3) 0.08 
    History of falls 69 (9.9) 40 (10.3) 29 (9.5) 0.71 
Bleeding history         
   GI hemorrhagesg 48 (6.9) 33 (8.5) 15 (4.9) 0.06 
   Non-GI hemorrhages 52 (7.5) 27 (7.0) 25 (8.1) 0.56 
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interval (CI).  All regression models were 
performed separately with and without miss-
ing fields; the data were unchanged in both 
models. 
 
Results 
 
Demographic characteristics of patients with 
atrial fibrillation are shown in Table 1.  The 
main study population consisted of 695 pa-
tients on warfarin alone or combination ther-
apy who met the inclusion criteria.  We sepa-
rated patients into the warfarin only or the 
warfarin plus aspirin groups.  These groups  
had similar characteristics including age, 
rates of paroxysmal atrial fibrillation,  
 
CHADS2 scores, and other comorbidities as 
specified in Table 1.  The groups also had 
similar exposure times to warfarin at the start 
of the study which did not differ significantly 
(p=0.36).  Approximately half of the patients 
in each group were on warfarin for over a 
year before the study start date, 218 (56.2%) 
in the warfarin only group and 152 (49.5%) 
in the combination group.  A sizable portion 
of each group initiated warfarin therapy dur-
ing the study period including 102 (26.3%) 
in the warfarin alone group and 96 (30.9%) 
in the combination group. 
 
Overall, 44.2% of patients took aspirin and 
warfarin in combination for some length of 
 
Table 2: Patient medication profile 
Medication Overall Warfarin Combination p Value 
Aspirin, n (%)         
    81 mg - - 246 (80.1) - 
    162 mg - - 10 (3.3) - 
    325 mg - - 51 (16.6) - 
Beta blocker 477 (68.6) 250 (64.4) 227 (72.9) 0.007 
Dihydropyridine CCBa 122 (17.6) 68 (17.5) 54 (17.6) 0.98 
Non-dihydropyridine CCB 92 (13.2) 60 (15.5) 32 (10.4) 0.05 
Anti-arrhythmicb 168 (24.2) 77 (19.9) 91 (29.6) 0.003 
Diuretic 395 (56.8) 219 (56.4) 176 (57.3) 0.82 
Statin 457 (65.8) 214 (55.2) 243 (79.2) <0.001 
ACEI/ARBc 426 (61.3) 214 (55.2) 212 (69.1) <0.001 
Digoxin 127 (18.3) 73 (18.8) 54 (17.59) 0.68 
a CCB = Calcium channel blockers 
b Includes class Ia, Ib, Ic, and class III anti-arrhythmic medications. 
c ACE/ARB = Angiotensin converting enzyme inhibitor/Angiotensin receptor blocker 
a Warfarin exposure as of June 1, 2007. Patients denoted as “None” started warfarin on or after June 1, 2007. 
b CABG = Coronary artery bypass grafting surgery 
c TIA = Transient ischemic attack 
d Documented history of chronic renal failure and/or persistently elevated creatinine ≥1.5mg/dL 
e Liver disease was defined as any document history of hepatitis B or C, cirrhosis, hepatic steatosis, or persistently 
abnormal liver function 
f Any history of malignancy excluding basal cell carcinoma 
g GI = Gastrointestinal 
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Table 3: Hemorrhagic outcomes 
Variable Warfarin Combination p Value 
Any Hemorrhagea 27 (5.2) 24 (7.0) 0.29 
Major 17 (3.4) 9 (2.8) 0.62 
INR (SD)b 4.27 (±3.1) 3.13 (±1.5) 0.049
c 
Bleed Types       
     Intracranial 5 (18.5) 2 (8.3) 0.41 
     Gastrointestinal 8 (29.6) 8 (33.3) 0.64 
a Includes both major and minor hemorrhages. 
b INR=International normalized ratio. INR measured on admission for hemorrhage or within 2 days prior to the 
admission. Most patients had INRs on admission recorded, 4 patients did not. SD = standard deviation 
c One-tailed 
 
Table 4: Characteristics of patients who hemorrhaged 
Characteristic Warfarin 
(n=27) 
Combination 
(n=24) 
p Value 
Age 77.9 73.3 0.10 
Female 13 (48.1) 7 (29.2) 0.17 
Warfarin Exposure Timea     0.03 
    None 3 (11.1) 11 (45.8)   
    <90 days 3 (11.1) 3 (12.5)   
    ≥90 days but <1 year 2 (3.9) 2 (3.9)   
    ≥1 year 19 (70.4) 8 (33.3)   
Target INRb       
   1.7-2.0 1 (3.7) 0 (0)   
   1.8-2.2 1 (3.7) 0 (0)   
   2.0-2.5 0 (0) 2 (8.3)   
   2.5-3.0 0 (0) 1 (4.2)   
   2.0-3.0 25 (92.6) 21 (87.5)   
Bleeding history 12 (44.4) 5 (20.8) 0.07 
   GI hemorrhages 5 (18.5) 3 (12.5) 0.56 
   Non-GI hemorrhages 7 (25.9) 4 (16.7) 0.42 
a Warfarin exposure as of June 1, 2007. Patients denoted as “None” started warfarin on or after June 1, 2007. 
b Target INR specified in patient anticoagulation clinic record. 
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years) (p=0.62).  Intracranial hemorrhages 
accounted for 7 (0.87% per 100-people 
years) events overall with no significant dif-
ference between the groups (p=0.40).  Gas-
trointestinal bleeding was the most common 
hemorrhage type and it accounted for 16 
(2.0% per 100-people years) events.  Each 
group experienced 8 gastrointestinal hemor-
rhages which accounted for 29.6% of bleeds 
in the warfarin only groups and 33.3% of 
bleeds in the combination group (p=0.64). 
No patients died of anticoagulation related 
hemorrhages. 
 
Table 3 also shows the duration of exposure 
to warfarin before June 1, 2007 in relation to 
hemorrhagic events.  In comparing the dura-
tion of warfarin exposure between the groups 
with hemorrhages, the combination group 
was more likely to have started warfarin dur-
ing the study period than the warfarin only 
group.  Of the patients in the combination 
group who bled, 11 (45.8%) started warfarin 
during the study period compared to 3 
(11.1%) in the warfarin only group (p=0.03). 
Patients in the warfarin only group who had 
hemorrhages were likely to have been on 
warfarin for longer than one year (70.4% vs 
33.3%). 
 
The INR measured on presentation for any 
hemorrhage (or within 2 days of presentation 
in 4 cases) is shown in Table 3.  The INR 
values for the warfarin alone group averaged 
4.27 ±3.1 compared to the combination 
group which averaged 3.13 ±1.5 (one-tailed 
p=0.049).  The target INR ranges for these 
patients are shown in Table 4.  The groups 
had similar target INR ranges with the major-
ity of patients targeted at an INR between 2.0 
-3.0. 
 
A multivariate analysis revealed that patients 
with a history of a prior gastrointestinal hem-
orrhage were 2.6 times more likely to have a 
bleed of any type compared with those who 
time during the study period.  Cardiovascular 
risk factors were strong predictors for combi-
nation therapy use.  Patients in the combina-
tion group had higher rates of documented 
dyslipidemia (77.5% vs 61.1%, p<0.001), 
prior myocardial infarction (31.9% vs 8.8%, 
p<0.001), coronary artery stent placement 
(18.2% vs 5.2%, p<0.001), coronary artery 
bypass grafting surgery (23.8% vs 8.5%, 
p<0.001), and diabetes mellitus (31.6% vs 
22.4%, p<0.001).  Males were more likely to 
be on combination therapy than females 
(69.7% vs 50.3%, p<0.001).  Patients with an 
implanted pacemaker and/or cardiac defibril-
lator were more likely to be on combination 
therapy also (26.4% vs 19.6%, p=0.03).  His-
tory of bleeding was similar in both groups. 
Other characteristics such as hypertension 
and a history of prior stroke or transient is-
chemic attack did not have a statistically sig-
nificant difference between groups. 
 
Concurrent medications are listed in Table 2. 
Of patients on combination therapy, 246 
(80.1%) took 81 mg, 10 (3.3%) took 162mg, 
and 51 (16.6%) took 325mg daily.  Patients 
on combination therapy were more likely to 
have concomitant use of statins, beta-
blockers, angiotensin converting enzyme in-
hibitors or angiotensin receptor blockers, as 
well as class Ia, Ib, Ic, and III anti-
arrhythmic medications. 
 
Tables 3 and 4 list the characteristics of the 
patients with hemorrhages and their bleeding 
events.  Of 695 patients, 51 (7.3% of all pa-
tients or 6.3% per 100-people years) experi-
enced hemorrhages of which 27 (5.2% per 
100-people years) were on warfarin only and 
24 (7.0% per 100-people years) were on 
combination therapy (p=0.29).  Major hem-
orrhages comprised 26 (51.0%) of the 51 
hemorrhages.  Of the major hemorrhages, the 
warfarin only group experienced 17 (3.4% 
per 100-people years) and the combination 
group experienced 9 (2.8% per 100-people 
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did not have such a history (95% CI, 1.08-
6.06).  Likewise, patients with a history of 
non-gastrointestinal hemorrhages were 3.8 
times more likely to have a bleed of any type 
compared with those who did not have a pri-
or bleed (95% CI, 1.79-8.13).  Patients in the 
combination group tended to be less likely to 
have a history of GI bleeding compared with 
the warfarin alone group (p=0.06). 
 
In addition to the main study group of 695 
patients, a small subgroup of 36 patients on 
triple therapy with warfarin, aspirin, and 
clopidogrel was identified.  These patients 
were not included in the main study group, 
but we did observe and take note of a high 
rate of hemorrhages in this group.  Six of the 
thirty-six patients (16.7%) experienced hem-
orrhagic events during the study period.  
These events included two major GI bleeds, 
three minor GI bleeds, and one minor sponta-
neous diffuse subcutaneous hemorrhage. 
 
Discussion 
 
Combination therapy with warfarin and aspi-
rin is highly prevalent in patients with atrial 
fibrillation.  Patients on combination therapy 
were more likely to be male with a history of 
coronary artery disease, have had interven-
tions for coronary artery disease, and have 
diabetes mellitus.  When used in combina-
tion, the most common dose of aspirin was 
81 mg daily.  Patients in this study who were 
on combination therapy were not statistically 
more likely to have hemorrhages when com-
pared to the warfarin alone group.  Both 
groups had hemorrhage rates similar to those 
reported by other studies.9,13,16  However, 
patients on combination therapy had on aver-
age lower INR measurements when they pre-
sented with bleeding.  This finding suggests 
that combination therapy may alter the risk 
of bleeding independent of the INR level. 
Triple therapy deserves further research as it 
appears to be associated with a much higher 
risk of bleeding, particularly gastrointestinal 
bleeding.  Though the sample size was small 
in this study, other studies have found that 
triple therapy dramatically increases the risk 
of major bleeding compared to other an-
tithrombotic regimens including warfarin 
alone.17,18 
 
This study does not show a statistically sig-
nificant difference in hemorrhagic outcomes 
between warfarin alone and combination 
warfarin and aspirin.  In considering our re-
sults in the context of the current literature 
on this topic, we recommend caution in using 
combination therapy.  No strong data sub-
stantiates a benefit to the aspirin and warfarin 
combination, and several prior studies have 
demonstrated an increased rate of major 
hemorrhage with combination thera-
py.13,14,19,20  Combination therapy appears to 
be as safe as monotherapy in our study popu-
lation which was closely managed by a dedi-
cated physician and nurse practitioner staffed 
anticoagulation clinic.  Patients in this study 
received frequent and well documented 
counseling about the hemorrhagic risks of 
warfarin.  Early identification of bleeding 
events and elevated INR measurements by 
the anticoagulation clinic led to interventions 
such as modifying warfarin dosing, altering 
doses of other medications, counseling on 
behavioral factors, and direction to go to the 
emergency department.  We believe these 
interventions may have reduced major bleeds 
and likely prevented bleeding in general.  
Bleeding risk may vary depending on the 
practice settings.  Clinical pharmacy antico-
agulation services, such as the anticoagula-
tion clinic in this study, have been shown to 
provide closer monitoring and improved out-
comes compared with care provided by per-
sonal physicians alone.21,22 
 
The interpretation of this study must be tem-
pered with a consideration of its limitations. 
The reporting of hemorrhagic events was 
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heterogeneous.  Most patients presented to 
the university hospital or its affiliated institu-
tions which reported bleeding events to the 
anticoagulation clinic.  Some patients pre-
sented to outside hospitals and later reported 
their bleeding to the anticoagulation clinic or 
to their primary care physician whose rec-
ords we reviewed.  Therefore, hemorrhage 
rates may be understated as they depended 
on patient self-reporting.  The patients in this 
study had a high level of coronary artery dis-
ease and other cardiac conditions, which may 
account for the high incidence of combina-
tion therapy.  Patient populations with less 
cardiac disease may find a lower incidence of 
combination therapy.  In addition, our pa-
tients were exclusively managed by the anti-
coagulation clinic.  The findings of this study 
may not be generally applicable to all patient 
settings.  Finally, this study did not systemat-
ically evaluate outcomes other than hemor-
rhages.  Therefore, this study was not 
equipped to examine efficacy of treatment 
with warfarin versus warfarin plus aspirin. 
 
In conclusion, in this study of patients with 
atrial fibrillation, combination therapy with 
warfarin and aspirin did not statistically in-
crease the risk of hemorrhage.  A prior histo-
ry of any type of bleeding was associated 
with an increased risk of future bleeding 
when using warfarin.  Physicians should ex-
ercise caution in prescribing warfarin either 
alone or in combination when there has been 
a history of bleeding.  Patients on combina-
tion therapy frequently hemorrhaged with 
INR levels at or near therapeutic levels, sug-
gesting that they may need closer monitoring 
to ensure that the target INR is not exceeded. 
Further study of the relationship between 
combination therapy and INR accuracy in 
predicting hemorrhage is needed.  The issue 
of triple therapy, which was only tangentially 
examined in this study, requires closer exam-
ination as it appears to be associated with a 
high rate of hemorrhages. 
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